Fluorescence Optical Imaging Technology
By Biotechdaily staff writers
Posted on 29 Aug 2003
A new fluorescence optical imaging technology allows in vivo imaging of molecular processes, which is expected to speed the research and development of new drugs.Posted on 29 Aug 2003
The technology, called bonSAI, is designed to aid drug-target identification and early prioritization of candidate compounds, speeding research and decreasing time to market. Molecular imaging allows noninvasive measurement of molecular and biologic processes, probing the molecular abnormalities that are the origin of disease rather than imaging the resulting conditions caused by the disease.
The technology was developed by Siemens Medical Solutions (Erlangen, Germany) in collaboration with Dr. Ralph Weissleder, M.D., Ph.D, director of the Center for Molecular Imaging Research at Massachusetts General Hospital (MGH, Boston, USA). The bonsai technology also has broad applications in basic academic research at an affordable price, states Siemens.
"The adaptation of fluorescent optical techniques to diagnostic imaging is now changing the way we visualize molecular processes in vivo and ultimately, in the clinic,” said Dr. Weissleder.
Related Links:
Siemens Medical
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Hemodynamic System Monitor
OptoMonitor
Alcohol Testing Device
Dräger Alcotest 7000
